Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Interferon-beta treatment in patients with multiple sclerosis does not alter CYP2C19 or CYP2D6 activity.

British journal of clinical pharmacology - 1 Sept 2003

Hellman Karin, Roos Ewa, Osterlund Anna, Wahlberg Anneli, Gustafsson Lars L, Bertilsson Leif, Fredrikson Sten

Abstract excerpt

AIMS: To determine CYP2C19 and CYP2D6 activity in patients with multiple sclerosis (MS) before and during interferon (IFN)-beta treatment. METHODS: CYP2C19 and CYP2D6 activities were assessed using the probe drugs mephenytoin and debrisoquine, respectively. Urinary mephenytoin (S/R) and debrisoqu...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aryl Hydrocarbon Hydroxylases
Share to Cytochrome P-450 CYP2C19
Share to Cytochrome P-450 CYP2D6

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotype

Share to Interferon-beta

Share to Mixed Function Oxygenases

Share to Multiple Sclerosis

Share to Phenotype

Source

Open in PubMed Open full text

Identifiers

PMID: 12919185
DOI: 10.1046/j.0306-5251.2003.01859.x
PMCID: PMC1884353

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-12919185-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Interferon-beta treatment in patients with multiple sclerosis does not alter CYP2C19 or CYP2D6 activity.PMID 12919185Read ↗

Effect of isotretinoin on CYP2D6 and CYP3A activity in patients with severe acne.Semantic proximity Read ↗

CYP2D6 polymorphism in systemic lupus erythematosus patients.Semantic proximity Read ↗

Growth hormone does not alter CYP2A6 activity in growth hormone-deficient children.Semantic proximity Read ↗

Lack of effect of chloroquine on the debrisoquine (CYP2D6 and S-mephenytoin (CYP2C19) hydroxylation phenotypes.Semantic proximity Read ↗

Pharmacogenomics of interferon-β in multiple sclerosis: what has been accomplished and how can we ensure future progress?Semantic proximity Read ↗

Debrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents.Semantic proximity Read ↗

Hepatotoxicity of Drugs Used in Multiple Sclerosis, Diagnostic Challenge, and the Role of HLA Genotype Susceptibility.Semantic proximity Read ↗

Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population. Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 probe drugs.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.